Please ensure Javascript is enabled for purposes of website accessibility

Researchers Discover Cannabis Compound That May Be 30 Times More Potent Than THC

By David Jagielski – Feb 3, 2020 at 4:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The presence of THCP may help explain why some strains have more of an effect on users than you'd expect based on their THC levels.

New research out of Italy suggests there could be a much more potent cannabis compound than tetrahydrocannabinol (THC). Scientists have found a new psychoactive substance in the plant called tetrahydrocannabiphorol (THCP), which they believe could be more than 30 times stronger. Researchers measured the impact of THCP in a lab and found that like THC, the compounded attached to cannabinoid receptors in the body but bonded to them 33 times more strongly, indicating it's possible for THCP to disrupt mental and physical functions even more than THC. 

Dr. Cinzia Citti, who is the study's lead author, believes this helps explain why some strains behave differently than one would expect based solely on their THC levels. Citti said, "In cannabis varieties where THC is present in very low concentrations, then we can think that the presence of another, more active cannabinoid can explain those effects."

While this discovery of THCP suggests the potential for creating marijuana products that give users a more intense high, the researchers are also optimistic about the possibility of uncovering health benefits related to THCP.

Cannabis plant.

Image source: Getty Images.

Research a key focus for marijuana companies

There's a big need for more cannabis research to be done, and industry leaders Canopy Growth (CGC -8.55%) and Aurora Cannabis (ACB -3.85%) have played significant roles in trying to learn more about the potential benefits of using cannabis.

Last year, Aurora partnered with the UFC (Ultimate Fighting Championship) -- the two plan to jointly study and develop hemp-derived cannabidiol (CBD) products that could help treat athletes with injuries. Canopy Growth, meanwhile, has partnered with ex-athletes from the National Hockey League to determine if cannabis be useful in helping to treat post-concussion diseases, including post-traumatic stress disorder and depression.

Over the past 12 months, those two marijuana companies alone have spent more than 50 million Canadian dollars combined on research and development. 

 

David Jagielski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Canopy Growth Stock Quote
Canopy Growth
CGC
$2.78 (-8.55%) $0.26
Aurora Cannabis Stock Quote
Aurora Cannabis
ACB
$1.25 (-3.85%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.